Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Roche Holding AG | 243 |
| 2 | Bayer AG | 231 |
| 3 | Gilead Sciences Inc | 213 |
| 4 | Dana Farber Cancer Institute Inc | 129 |
| 5 | Kymera Therapeutics Inc | 116 |
| 6 | AstraZeneca PLC | 114 |
| 7 | Institut National de la Santé et de la Recherche Médicale | 103 |
| 8 | The University of Texas System | 102 |
| 9 | C.H. Boehringer Sohn AG and Co KG | 101 |
| 10 | Revolution Medicines Inc | 100 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 8,393 |
| 2 | A61K | Medicinal preparations | 8,091 |
| 3 | C07D | Heterocyclic compounds | 4,482 |
| 4 | C07K | Peptides | 2,453 |
| 5 | C12N | Microorganisms, enzymes | 976 |
| 6 | C12Q | Measuring/testing involving enzymes | 876 |
| 7 | G01N | Investigating / analysing materials | 809 |
| 8 | C07B | General methods of organic chemistry | 630 |
| 9 | C07F | Organometallic compounds | 521 |
| 10 | Y02A | Climate change adaptation | 390 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND "AZD9291 ANILINE" OR A SALT THEREOF | 2017 | AstraZeneca PLC | 11 |
| A kind of Osimertinib preparation method | 2017 | 7 | |
| OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | 2019 | AstraZeneca PLC | 4 |
| AN IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB MESYLATE | 2021 | Natco Pharma Ltd | 3 |
| Anticancer compound osimertinib and synthesis method thereof | 2016 | 2 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 59 |
| 2017 | 107 |
| 2018 | 160 |
| 2019 | 190 |
| 2020 | 251 |
| 2021 | 241 |
| 2022 | 200 |
| 2023 | 235 |
| 2024 | 241 |
| 2025 | 83 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Suresh S. Ramalingam | Emory University | 27 |
| 2 | James Chih‐Hsin Yang | National Taiwan University Hospital | 21 |
| 3 | Yi‐Long Wu | Guangdong Academy of Medical Sciences | 21 |
| 4 | Myung‐Ju Ahn | Samsung Medical Center | 20 |
| 5 | Byoung Chul Cho | Yonsei University | 19 |
| 6 | Helena A. Yu | Memorial Sloan Kettering Cancer Center | 15 |
| 7 | Pasi A. Jänne | Dana-Farber Cancer Institute | 15 |
| 8 | Filippo de Marinis | European Institute of Oncology | 14 |
| 9 | Yong He | Daping Hospital | 13 |
| 10 | Terufumi Kato | Kanagawa Prefectural Hospital Organization | 13 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib | 2004 | 11559 | Lung Cancer Diagnosis and Treatment |
| Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer | 2017 | 5403 | Lung Cancer Diagnosis and Treatment |
| Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer | 2016 | 3383 | Lung Cancer Diagnosis and Treatment |
| Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC | 2019 | 2885 | Lung Cancer Diagnosis and Treatment |
| AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer | 2014 | 2268 | Lung Cancer Treatments and Mutations |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Tagrisso?
What are the alternative names for this compound?
Which organizations hold the most patents related to Tagrisso?
How has research activity on Tagrisso trended over time?
What are the leading scientific focuses in Tagrisso research?